Misplaced Pages

Avadel Pharmaceuticals

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Flamel Technologies) Specialty pharmaceutical company

The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Avadel Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (March 2014) (Learn how and when to remove this message)
Avadel Pharmaceuticals plc
Company typePublic
Traded asNasdaq: AVDL
Industry
  • Healthcare
  • Pharmaceutical
Founded1990; 35 years ago (1990)
HeadquartersDublin, Ireland
Key people
Revenue$ 150.2M (Dec31, 2016)
Websitewww.avadel.com

Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

The company was founded as Flamel Technologies SA in Lyon, France in 1990.

The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.

On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.

On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.

In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.

In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate.

References

  1. "Company Key Statistics".
  2. "Investor Home". investors.avadel.com. Retrieved 26 June 2017.
  3. "Presentations | Investors | Avadel Pharmaceuticals". investors.avadel.com. Retrieved 17 July 2017.
  4. "About Us". eclatpharma.com. Retrieved 29 December 2014.
  5. "Flamel Technologies Announces Acquisition of Éclat Pharmaceuticals". businesswire.com. 14 March 2012. Retrieved 29 December 2014.
  6. "Flamel Technologies Acquires FSC Pediatrics". marketwired.com. 8 February 2016. Retrieved 7 March 2017.
  7. "Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc". globenewswire.com (Press release). 3 January 2017. Retrieved 7 March 2017.
  8. "Avadel chief executive resigns suddenly". The Irish Times. 3 January 2019. Archived from the original on 3 January 2019. Retrieved 30 October 2020.
  9. "Avadel Specialty Pharmaceuticals files for Chapter 11 bankruptcy". Wall Street Journal. 7 February 2019. Retrieved 24 February 2023.
  10. Brooks, Megan. "FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy". Medscape. Retrieved 14 July 2023.

External links

Stub icon 1 Stub icon 2

This Irish company article is a stub. You can help Misplaced Pages by expanding it.

Categories: